Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

January 5, 2018: By Jon Swedien

Legal issuePershing Square and Valeant Pharmaceuticals have agreed to pay $290 million to settle a lawsuit accusing the companies of insider trading before making a bid to buy Allergan in 2014, both companies announced in late December 2017.

However, a federal judge still must approve the deal.

US District Judge David Carter has questioned the proposed settlement, saying he has “substantial questions whether the settlement amount is reasonable and fair.” Carter set a hearing for Jan. 16 for attorneys from both corporations and the plaintiffs to explain their positions on the deal, according to media reports.

Both companies have said they are not guilty of the insider trading charges brought on behalf of investors who sold Allergan shares in the two months before the companies’ unsolicited $51 billion bid for Allergan.

Pershing Square CEO Bill Ackman and Valeant CEO Joseph Papa—who took the position in 2016 after the alleged insider trading—both said the settlement was in their companies’ best interest because it would allow them to move on.

Under the proposed settlement, Pershing Square will pay about two-thirds of the settlement, or $193.75 million. Valeant will pay about a third, or $96.25 million.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales